These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27673443)

  • 1. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
    Post FA; Tebas P; Clarke A; Cotte L; Short WR; Abram ME; Jiang S; Cheng A; Das M; Fordyce MW
    J Acquir Immune Defic Syndr; 2017 Feb; 74(2):180-184. PubMed ID: 27673443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.
    Maggiolo F; Rizzardini G; Raffi F; Pulido F; Mateo-Garcia MG; Molina JM; Ong E; Shao Y; Piontkowsky D; Das M; McNicholl I; Haubrich R
    Lancet HIV; 2019 Oct; 6(10):e655-e666. PubMed ID: 31578954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
    Pozniak A; Arribas JR; Gathe J; Gupta SK; Post FA; Bloch M; Avihingsanon A; Crofoot G; Benson P; Lichtenstein K; Ramgopal M; Chetchotisakd P; Custodio JM; Abram ME; Wei X; Cheng A; McCallister S; SenGupta D; Fordyce MW;
    J Acquir Immune Defic Syndr; 2016 Apr; 71(5):530-7. PubMed ID: 26627107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients.
    Huang YS; Cheng CY; Sun HY; Cheng SH; Lu PL; Lee CH; Lee YT; Tsai HC; Yang CJ; Liu CE; Liou BH; Lin SP; Huang SH; Ho MW; Tang HJ; Hung CC;
    Microbiol Spectr; 2023 Jun; 11(3):e0512522. PubMed ID: 36988457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
    Angione SA; Cherian SM; Özdener AE
    J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.
    Arribas JR; DeJesus E; van Lunzen J; Zurawski C; Doroana M; Towner W; Lazzarin A; Nelson M; McColl D; Andreatta K; Swamy R; Szwarcberg J; Nguyen T
    HIV Clin Trials; 2017 May; 18(3):118-125. PubMed ID: 28555519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.
    Rizzardini G; Gori A; Miralles C; Olalla J; Molina JM; Raffi F; Kumar P; Antinori A; Ramgopal M; Stellbrink HJ; Das M; Chu H; Ram R; Garner W; Shao Y; Chuck SK; Piontkowsky D; Haubrich RH
    AIDS; 2019 Aug; 33(10):1583-1593. PubMed ID: 31305329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults.
    Huhn GD; Tebas P; Gallant J; Wilkin T; Cheng A; Yan M; Zhong L; Callebaut C; Custodio JM; Fordyce MW; Das M; McCallister S
    J Acquir Immune Defic Syndr; 2017 Feb; 74(2):193-200. PubMed ID: 27753684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
    Greig SL; Deeks ED
    Drugs; 2016 Jun; 76(9):957-68. PubMed ID: 27189707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients.
    Huang YS; Cheng CY; Liou BH; Lu PL; Cheng SH; Lee YT; Liu CE; Sun HY; Yang CJ; Tang HJ; Lin SP; Ho MW; Huang SH; Tsai HC; Lee CH; Hung CC;
    J Acquir Immune Defic Syndr; 2021 Apr; 86(4):473-481. PubMed ID: 33273214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial.
    Natukunda E; Gaur AH; Kosalaraksa P; Batra J; Rakhmanina N; Porter D; Shao Y; Zhang H; Pikora C; Rhee MS
    Lancet Child Adolesc Health; 2017 Sep; 1(1):27-34. PubMed ID: 30169223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial.
    Post FA; Yazdanpanah Y; Schembri G; Lazzarin A; Reynes J; Maggiolo F; Yan M; Abram ME; Tran-Muchowski C; Cheng A; Rhee MS
    HIV Clin Trials; 2017 May; 18(3):135-140. PubMed ID: 28303753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF.
    Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T
    Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.
    Eron JJ; Lelievre JD; Kalayjian R; Slim J; Wurapa AK; Stephens JL; McDonald C; Cua E; Wilkin A; Schmied B; McKellar M; Cox S; Majeed SR; Jiang S; Cheng A; Das M; SenGupta D
    Lancet HIV; 2018 Dec; ():. PubMed ID: 30555051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
    Eron JJ; Orkin C; Gallant J; Molina JM; Negredo E; Antinori A; Mills A; Reynes J; Van Landuyt E; Lathouwers E; Hufkens V; Jezorwski J; Vanveggel S; Opsomer M;
    AIDS; 2018 Jul; 32(11):1431-1442. PubMed ID: 29683855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    J Clin Virol; 2018 Jun; 103():37-42. PubMed ID: 29627709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide.
    Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Wei X; Collins SE; Cheng A
    AIDS; 2018 Jul; 32(12):1723-1725. PubMed ID: 29794828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
    Post FA; Winston J; Andrade-Villanueva JF; Fisher M; Liu Y; Beraud C; Abram ME; Graham H; Rhee MS; Cheng AK; Szwarcberg J;
    J Acquir Immune Defic Syndr; 2015 Mar; 68(3):310-3. PubMed ID: 25469527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.
    LaFleur J; Bress AP; Esker S; Knippenberg K; Crook J; Nyman H; Bedimo R; Tebas P; Rosenblatt L
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):325-330. PubMed ID: 29210830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.